CORIUM INNOVATIONS TO MEET WITH GLOBAL BIO COMPANIES FOR NEXT-GENERATION TRANSDERMAL AND ORAL THIN FILM PRODUCT PARTNERSHIPS

Grand Rapids, Michigan, June 1, 2026 – Corium Innovations, Inc., a leading full-service contract development and manufacturing organization (CDMO) specializing in advanced drug delivery technologies, today announced it will showcase both its proprietary transdermal and oral thin film delivery platforms at the 2026 BIO International Convention, taking place June 22–25 in San Diego, California. During the conference, the company will participate in BIO One-on-One Partnering™ meetings to engage with pharmaceutical, biotech and strategic partners seeking differentiated drug delivery, development and clinical/commercial manufacturing capabilities.

“BIO International Convention provides an important opportunity to connect with companies that are looking for innovative, scalable drug delivery solutions and experienced development partners,” said Dr. Mark Sirgo, Chief Executive Officer of Corium Innovations. “As demand continues to grow for differentiated delivery technologies that can improve adherence, patient experience and product lifecycle value, Corium Innovations is uniquely positioned to support partners from formulation and clinical development through commercial manufacturing. We look forward to engaging with new collaborators through the BIO partnering platform this year.”

With annual manufacturing capacity of more than 200 million transdermal patches/films at its 200,000 square foot, FDA, DEA and ISO registered facility in Grand Rapids, Michigan, Corium Innovations maintains fully integrated research, development, and analytical capabilities. Corium Innovations, with 25 years of developing and manufacturing groundbreaking transdermal and oral thin film delivery systems including over 100+ patents, brings the best of these proprietary delivery platforms to different patient and consumer groups in customary or challenging usage situations.

Corium Innovations’ proprietary Corplex® transdermal innovation platform breaks new ground in drug delivery with a proprietary mix of adhesives, polymers and liners that can be adjusted for almost any use situation. From Crest® brand teeth whitening strips, to the first and only 7-day, low-dose estrogen birth control patch, Corplex® is helping millions of people get the help and benefits they are seeking in a way that works better.

About Corium Innovations

Headquartered in Grand Rapids, Michigan, Corium Innovations is a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies. With a track record spanning nearly 30 years, Corium Innovations offers end-to-end solutions to its partners, from formulation and product development work, through commercial-scale manufacturing and packaging. The company's success is enabled by its state-of-the-art facilities, highly tenured operational leadership, and its proprietary proven drug delivery technology Corplex®. For more information, visit www.coriuminv.com.

To connect with Corium Innovations during the conference, reach out to Kevin Ostrander, Chief Business Officer, Corium Innovations, at Kevin.ostrander@coriumintl.com.

About Gurnet Point Capital

Point Capital is a leading healthcare fund that invests in de-risked life sciences companies. Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution. These companies become partners not just because of their capacity to generate economic value, but also because of their potential to deliver social impact. Gurnet Point’s team of highly experienced industry executives works closely with its portfolio companies, with an active approach driving operational transformation and outsized returns. For more information, visit www.gurnetpointcapital.com.

About Webster Equity Partners

Founded in 2003, Webster is a private equity firm that focuses on high impact growth strategies that seek to deliver optimal outcomes for our investors, portfolio companies and the communities that we serve. Our mission is to deliver superior returns to our partners through the investment in and development of purpose driven patient-centric healthcare organizations dedicated to providing best of class clinical care and service to their patients. For more information, visit www.websterequitypartners.com.

Contact

Gartman PR
gartmanpr@gmail.com
202-413-4226